Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
Recruiting
N/A
Interventional Study
Stroke
Transient Ischemic Attack (TIA)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 89
- Sex
- Any
- Study type
- Interventional
- Purpose
- Health Services Research
- Participants needed
- 200 (estimated)
- Sponsor
- University of Alabama at Birmingham · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients 18-89 years of age
* admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA
* eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well)
Excl…
Contacts